Abatacept for Graft Versus Host Disease Prophylaxis in Patients 60 Years and Older Receiving Mismatched Unrelated Donor Transplantation for Hematologic Malignancies
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2023 Category: Hematology Authors: Amelia A. Langston, Benjamin K. Watkins, Sharmila Raghunandan, Lev Gorfinkel, Adrianna Lynn Westbrook, Scott Gillespie, Brandi Bratrude, Kayla Betz, Aleksandra Petrovic, Yvonne Suessmuth, John Horan, Leslie S. Kean, Muna Qayed Tags: POSTER SESSION: GRAFT-VERSUS-HOST AND GRAFT VERSUS TUMOR - CLINICAL: PREVENTION, TREATMENT AND BIOMARKERS Source Type: research
Impact of Abatacept in Patients with Inherited Bone Marrow Failure Syndromes
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2023 Category: Hematology Authors: Ms. Zahra Hudda, Nicholas J. Gloude, Adam Lane, Deborah Schiff, Eric Anderson, Parinda A. Mehta, Stella M. Davies, Kasiani Myers Tags: POSTER SESSION: GRAFT-VERSUS-HOST AND GRAFT VERSUS TUMOR - CLINICAL: PREVENTION, TREATMENT AND BIOMARKERS Source Type: research
Safety and Efficacy of Gvhd Prophylaxis with Abatacept and Reduced Dose Post-Transplant Cytoxan in Matched Unrelated and Matched Related Allogeneic Peripheral Stem Cell Transplants
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2023 Category: Hematology Authors: Yuliya Shestovska, Michael J Styler, Rashmi Khanal, Peter Abdelmessieh, Brittany Ballas, Michele Sorrentino, Anne Ojala, Henry Fung, Asya Varshavsky-Yanovsky Tags: POSTER SESSION: GRAFT-VERSUS-HOST AND GRAFT VERSUS TUMOR - CLINICAL: PREVENTION, TREATMENT AND BIOMARKERS Source Type: research
Mechanism of Success of Abatacept in Hematopoietic Stem Cell Transplantation: Pharmacokinetic-Pharmacodynamic (PK-PD) Analysis Demonstrates Greater Abatacept Exposure Decreases Acute Gvhd (AGVHD) Risk without Increasing Adverse Events
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2023 Category: Hematology Authors: Takuto Takahashi, Mahmoud Al-Kofahi, Mutaz Jaber, Amelia A. Langston, John Horan, Brandi Bratrude, Kayla Betz, Yvonne Suessmuth, Ben K. Watkins, Muna Qayed, Leslie S. Kean Tags: POSTER SESSION: GRAFT-VERSUS-HOST AND GRAFT VERSUS TUMOR - CLINICAL: PREVENTION, TREATMENT AND BIOMARKERS Source Type: research
Abatacept for the Prevention of Graft Versus Host Disease in Pediatric Patients Receiving 7/8 HLA-Mismatched Unrelated Transplant for Hematologic Malignancies: A Real-World Analysis
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2023 Category: Hematology Authors: Sharmila Raghunandan, Lev Gorfinkel, Brandi Bratrude, Kayla Betz, Yvonne Suessmuth, Kyle Hebert, Donna Neuberg, Kirsten M. Williams, Michelle Long Schoettler, Amelia A. Langston, Leslie S. Kean, Muna Qayed, John Horan, Ben K. Watkins Tags: POSTER SESSION: GRAFT-VERSUS-HOST AND GRAFT VERSUS TUMOR - CLINICAL: PREVENTION, TREATMENT AND BIOMARKERS Source Type: research
Early Breakthrough T Cell Proliferation Despite CNI/MTX Prophylaxis Is a Harbinger of Acute Gvhd (AGVHD) and Is Controlled By Abatacept: Mechanism of Success of the ABA2 Agvhd Prevention Trial
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2023 Category: Hematology Authors: Alexandre Albanese, Alal S Eran, Yvonne Suessmuth, Kayla Betz, Brandi Bratrude, Paula Keskula, Lorenzo S Cagnin, Amelia A. Langston, Muna Qayed, John Horan, Bruce R. Blazar, Ben K. Watkins, Leslie S. Kean Tags: POSTER SESSION: GRAFT-VERSUS-HOST AND GRAFT VERSUS TUMOR - CLINICAL: PREVENTION, TREATMENT AND BIOMARKERS Source Type: research
Phase Ib-II Study of Post-Transplant Cyclophosphamide, Abatacept and Short Course of Tacrolimus (CAST) for Graft-Versus-Host Disease Prevention Following Haploidentical Peripheral Blood Stem Cell Transplantation
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2023 Category: Hematology Authors: A Samer Al-Homsi, Frank Cirrone, Kelli Cole, J Andres-Suarez Londono, Sharon Gardner, Jingmei Hsu, Stephanie Wo, Kelsey Stocker, Judith Goldberg, Benjamin Levinson, Maher Abdul-Hay Tags: POSTER SESSION: GRAFT-VERSUS-HOST AND GRAFT VERSUS TUMOR - CLINICAL: PREVENTION, TREATMENT AND BIOMARKERS Source Type: research
Long-Term Outcome of Abatacept-Ptcy-Sirolimus Based Haploidentical HCT in Younger Patients with Nonmalignant Diseases
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2023 Category: Hematology Authors: Sarita Rani Jaiswal, Ashraf Saifullah, Jaganath Arunachalam, Rohit Lakhchaura, Mahak Agarwal, Prakash Baligar, Subhrajit Biswas, Suparno Chakrabarti Tags: ORAL ABSTRACT - SESSION K: GVHD - BASIC SCIENCE Source Type: research
Biological and immunosuppressive medications in pregnancy, breastfeeding and fertility in immune mediated diseases
CONCLUSIONS: In this context of chronic treatments with teratogenic potential, it is necessary to highlight the importance of pregnancy planning to select the safest drug. Given the quality of the available data, it is still necessary to continuously update the information, as well as to promote observational studies of cohorts of pregnant patients and men of childbearing age, including prospective studies, in order to generate more scientific evidence.PMID:36710223 | DOI:10.1016/j.farma.2022.12.005 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - January 29, 2023 Category: Drugs & Pharmacology Authors: Olatz Ibarra Barrueta Estela Garc ía Martín Piedad L ópez Sánchez Esther Ram írez Herráiz Vicente Merino Boh órquez Arantza Ais Larisgoitia Source Type: research
Biological and immunosuppressive medications in pregnancy, breastfeeding and fertility in immune mediated diseases
CONCLUSIONS: In this context of chronic treatments with teratogenic potential, it is necessary to highlight the importance of pregnancy planning to select the safest drug. Given the quality of the available data, it is still necessary to continuously update the information, as well as to promote observational studies of cohorts of pregnant patients and men of childbearing age, including prospective studies, in order to generate more scientific evidence.PMID:36710223 | DOI:10.1016/j.farma.2022.12.005 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - January 29, 2023 Category: Drugs & Pharmacology Authors: Olatz Ibarra Barrueta Estela Garc ía Martín Piedad L ópez Sánchez Esther Ram írez Herráiz Vicente Merino Boh órquez Arantza Ais Larisgoitia Source Type: research
Biological and immunosuppressive medications in pregnancy, breastfeeding and fertility in immune mediated diseases
CONCLUSIONS: In this context of chronic treatments with teratogenic potential, it is necessary to highlight the importance of pregnancy planning to select the safest drug. Given the quality of the available data, it is still necessary to continuously update the information, as well as to promote observational studies of cohorts of pregnant patients and men of childbearing age, including prospective studies, in order to generate more scientific evidence.PMID:36710223 | DOI:10.1016/j.farma.2022.12.005 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - January 29, 2023 Category: Drugs & Pharmacology Authors: Olatz Ibarra Barrueta Estela Garc ía Martín Piedad L ópez Sánchez Esther Ram írez Herráiz Vicente Merino Boh órquez Arantza Ais Larisgoitia Source Type: research
Selective CD28 blockade impacts T cell differentiation during homeostatic reconstitution following lymphodepletion
DiscussionThese data demonstrate that CD28 signaling impacts the differentiation of both CD4+ and CD8+ T cells during homeostatic reconstitution following lymphodepletion, resulting in a shift towards fewer activated memory T cells and more CD8+FoxP3+ T cells, a profile that may underpin the observed prolongation in allograft survival. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - January 24, 2023 Category: Allergy & Immunology Source Type: research
Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept Therapy
ConclusionsThis open-label study demonstrated abatacept may be beneficial for treatment-refractory JDM. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - January 19, 2023 Category: Rheumatology Authors: Rodolfo V. Curiel,
William Nguyen,
Gulnara Mamyrova,
Derek Jones,
Alison Ehrlich,
Kathleen A. Brindle,
Shahriar Haji ‐Momenian,
Robert Sheets,
Hanna Kim,
Olcay Y. Jones,
Lisa G. Rider,
for the Abatacept in Dermatomyositis (AID) Trial Investig Tags: Full Length Source Type: research
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
Conclusions
These updated EULAR recommendations provide consensus on RA management including safety, effectiveness and cost. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - January 3, 2023 Category: Rheumatology Authors: Smolen, J. S., Landewe, R. B. M., Bergstra, S. A., Kerschbaumer, A., Sepriano, A., Aletaha, D., Caporali, R., Edwards, C. J., Hyrich, K. L., Pope, J. E., de Souza, S., Stamm, T. A., Takeuchi, T., Verschueren, P., Winthrop, K. L., Balsa, A., Bathon, J. M., Tags: ARD, EULAR papers Recommendation Source Type: research
Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis
Conclusion
The results of this SLR, together with one SLR on safety of DMARD and one on glucocorticoids, informed the taskforce of the 2022 update of the EULAR recommendations for pharmacological management of RA. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - January 3, 2023 Category: Rheumatology Authors: Kerschbaumer, A., Sepriano, A., Bergstra, S. A., Smolen, J. S., van der Heijde, D., Caporali, R., Edwards, C. J., Verschueren, P., de Souza, S., Pope, J. E., Takeuchi, T., Hyrich, K. L., Winthrop, K. L., Aletaha, D., Stamm, T. A., Schoones, J. W., Landewe Tags: ARD, Rheumatoid arthritis Source Type: research
